ALL NEWS

Merck says experimental pill cuts worst effects of COVID-19

Oct 1, 2021, 7:18 AM
This undated image provided by Merck & Co. shows their new antiviral medication. Pharmaceutical...
This undated image provided by Merck & Co. shows their new antiviral medication. Pharmaceutical company Merck & Co. said Friday, Oct. 1, 2021, that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use. (Merck & Co. via AP)
(Merck & Co. via AP)

WASHINGTON (AP) — Drugmaker Merck said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use.

If cleared, the drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorized in the U.S. require an IV or injection.

Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and death as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered higher risk for severe disease due to health problems such as obesity, diabetes or heart disease.

Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck. The results were released by the company and have not been peer reviewed by outside experts, the usual procedure for vetting new medical research. Merck said it plans to present them at a future medical meeting.

An independent group of medical experts monitoring the trial recommended stopping it early because the interim results were so strong. That is typical when early results so clearly show a treatment works that there is no need for further testing before applying for authorization. Company executives said they plan submit the data for review by the Food and Drug Administration in coming days. Once the submission is complete, the FDA could make a decision within weeks — and, if approved, the drug could be on the market soon after.

“It exceeded what I thought the drug might be able to do in this clinical trial,” said Dr. Dean Li, vice president of Merck Research Laboratories. “When you see a 50% reduction in hospitalization or death that’s a substantial clinical impact.”

Side effects were reported by both groups in the Merck trial, but they were slightly more common among the group that received a dummy pill. The company did not specify the problems.

Patients take the pill twice a day for five days to complete a course of treatment.

Earlier study results showed the drug did not benefit patients who were already hospitalized with severe disease.

The U.S. has approved one antiviral drug, remdesivir, specifically for COVID-19, and allowed emergency use of three antibody therapies that help the immune system fight the virus. But all the drugs have to given by IV or injection at hospitals or medical clinics, and supplies have been stretched by the latest surge of the delta variant.

Health experts including the top U.S. infectious disease expert Dr. Anthony Fauci have long called for a convenient pill that patients could take when COVID-19 symptoms first appear, much the way the standard flu medication Tamiflu helps fight influenza. Such medications are seen as key to controlling future waves of infection and reducing the impact of the pandemic.

Merck’s pill works by interfering with the coronavirus’s ability to copy its genetic code and reproduce itself. It has shown similar activity against other viruses.

The U.S. government has committed to purchase 1.7 million doses of the drug if it is authorized by the FDA. Merck has said it can produce 10 million doses by the end of the year and has contracts with governments worldwide. The company has not announced prices.

Several other companies, including Pfizer and Roche, are studying similar drugs that could report results in the coming weeks and months.

Merck had planned to enroll more than 1,500 patients in its late-stage trial before the independent board stopped it early. The results reported Friday included patients enrolled across Latin America, Europe and Africa. Executives estimated about 10% of patients studied were from the U.S.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Today’s Top Stories

All News

CDC reports monkeypox cases....
Waverly Golden

CDC confirms five monkeypox cases in Utah

SALT LAKE CITY — The U.S. Centers for Disease Control and Prevention (CDC) confirmed a total of five monkeypox cases in Utah, earlier this morning. According to the Utah Department of Health, four of the cases are located in Salt Lake County and one in Utah County. On Tuesday, the total number of cases statewide […]
1 day ago
Downtown salt lake is pictured. Utah quality of life is declining according to new report....
Amie Schaeffer

New report shows quality of life for Utahns in decline

A report documenting the quality of life in Utah indicates that it might be in decline. Among the findings include a call for more affordable housing.
1 day ago
New York Gov. Kathy Hochul stands with Lieutenant governor Antonio Delgado during their primary ele...
STEVE PEOPLES AP National Politics Writer

Takeaways from first primaries since Roe v. Wade overturned

The abortion debate consumed the nation this week, but there was no race where it mattered more than Colorado's Republican primary for the U.S. Senate, where businessman Joe O'Dea became one of the only abortion-rights-supporting Republicans in the nation to win a statewide primary this year.
1 day ago
A ballot drop box is pictured. Those wanting to vote in the utah primary election can still vote in...
Amie Schaeffer

Utah primary election: Acceptable ID to bring for in-person voting

Utah's Primary Election is today. Voters need to be sure they have the right identification to cast their ballot.
2 days ago
bountiful porch thefts...
Dan Bammes

Bountiful woman arrested after allegedly stealing $6,000 from patient

Miller, who worked with the victim as a recreational therapist when the theft occurred.
2 days ago
A technician works on a component of Rocket Lab's Electron rocket ahead of the launch on the Mahia ...
NICK PERRY Associated Press

NASA hopes New Zealand launch will pave way for moon landing

The mission came together relatively quickly and cheaply for NASA, with the total mission cost put at $32.7 million.
2 days ago

Sponsored Articles

Tax Harassment...
Jordan Wilcox

The best strategies for dealing with IRS tax harassment | You have options!

Learn how to deal with IRS tax harassment. This guide will teach you how to stop IRS phone calls and letters, and how to handle an IRS audit.
spend a day at Bear Lake...
Bear Lake Convention and Visitors Bureau

You’ll love spending the day at Bear Lake | How to spend a day at Bear Lake

Bear Lake is a place that needs to be experienced. Spend a day at Bear Lake.
Curb Appeal...
Price's Guaranteed Doors

How to have the best of both worlds for your house | Home security and curb appeal

Protect your home and improve its curb appeal with the latest security solutions like beautiful garage doors and increased security systems.
Prescription opioids can be disposed of during National Prescription Take Back Day...
Know Your Script

Prescription opioid misuse | How to protect your family from the opioid epidemic

Studies have shown that prescription opioid misuse has increased since COVID-19. So what do you need to know about these opioids?
Follow @ikeyospe...

Tax Tuesday: The Most Common Mistakes People Make When Filing Their Taxes

Fortunately, for most average earners, they will not end up owing overpayments received for the Child Tax Credit in 2021.
Follow @ikeyospe...

Tax Tuesday: How will last year’s child tax credits affect you?

Fortunately, for most average earners, they will not end up owing overpayments received for the Child Tax Credit in 2021.
Merck says experimental pill cuts worst effects of COVID-19